Why is brain cancer so hard to treat?

The episode begins with an overview of brain cancers, highlighting their rarity yet devastating impact. Patients often face short life expectancy post-diagnosis, and the tumors are difficult to remove entirely. Standard treatments like radiation and chemotherapy don't always prevent the cancers from spreading. Dr. Michelle Monje discusses her two-decade focus on understanding the formation and interaction of brain tumors with healthy brain cells, emphasizing the immense challenges and importance of her research in this field.

Dr. Monje recounts her early experiences working with childhood brain cancer patients, especially with diffuse intrinsic pontine glioma (DIPG), a highly fatal cancer in children. Witnessing the rapid decline of a young patient deeply motivated her to find better understanding and treatments. She explains that, 20 years ago, knowledge about brain cancers was limited, partly due to technological constraints and the inherent difficulty in studying these inaccessible diseases. Her focus shifted towards neurobiology to uncover the roots of these cancers in brain development.

The episode describes how Dr. Monje leveraged her background in neural stem cell biology to develop models for studying brain tumors. Her breakthrough came from her patients' donated tumor tissues, allowing her team to culture tumor cells and create the first models for DIPG. These models opened new avenues for studying tumor behavior, potential therapies, and understanding how these cancers resemble developing brain cells.

Dr. Monje explains that brain cancer treatment is hampered by the blood-brain barrier and the widespread nature of tumors within the nervous system. Traditional approaches focusing solely on cancer cell vulnerabilities are insufficient because the interaction between tumors and the nervous system promotes growth and resistance. Research has uncovered that neural activity and electrical signaling between neurons and cancer cells play crucial roles in tumor progression.

Research by Dr. Monje and her team reveals that neural activity significantly promotes tumor growth. Cancer cells form synapses with neurons, and electrical activity in the brain enhances cancer proliferation and invasion. Disrupting this electrical communication, using existing medications such as anti-seizure drugs, offers promising therapeutic potential—some of which are already showing positive results in preclinical studies.

The podcast discusses innovative treatment strategies, including targeting electrical signaling pathways and using immunotherapies like CAR T-cell therapy. Dr. Monje shares her optimism about upcoming clinical trials that aim to test these approaches. She highlights the progress made, such as retrospective studies indicating better outcomes with certain anti-seizure medications and the promising results from animal models using engineered immune cells to target tumors.

Dr. Monje emphasizes that combining multiple therapeutic strategies—disrupting neural interactions, enhancing immune responses, and combining treatments—is crucial for effectively combating these cancers. Her motivation stems from her patients, and she is hopeful that ongoing research will lead to transformative progress. She also notes that insights gained in childhood brain cancers have broader implications for other cancers, including brain metastases and peripheral nerve interactions.